CARv3-TEAM-E T Cells for Glioblastoma
Trial Summary
What is the purpose of this trial?
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Do I need to stop taking my current medications for the trial?
Participants must stop taking certain medications before joining the trial. Specifically, they need to be 4 weeks from their last dose of alkylating therapy or immunotherapy and must wait for at least 5 half-lives from another investigational agent. However, no washout period is required for radiation therapy.
What data supports the effectiveness of the CARv3-TEAM-E T Cells treatment for glioblastoma?
Research shows that CAR T-cell therapy, which involves modifying a patient's own T cells to better target cancer cells, has shown promise in treating glioblastoma by activating the immune system and potentially improving the tumor environment. Although still in early stages, studies have observed some signs of effectiveness in patients with glioblastoma, suggesting that this approach could help in fighting this challenging cancer.12345
Is CARv3-TEAM-E T Cells therapy safe for humans?
How is the CARv3-TEAM-E T Cells treatment different from other treatments for glioblastoma?
The CARv3-TEAM-E T Cells treatment is unique because it uses genetically modified T cells to specifically target and attack glioblastoma cells, potentially overcoming the challenges of the tumor's location and immune evasion. This approach is different from traditional treatments as it aims to enhance the body's immune response directly against the tumor.3591011
Research Team
William Curry, MD
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
This trial is for adults with recurrent glioblastoma, a type of brain tumor. Participants must have had prior radiation, measurable disease, and be able to undergo an MRI. They should not have other ongoing serious illnesses or a history of certain cancers within the last 5 years (with some exceptions). Adequate organ function and agreement to use contraception are required.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Safety Run-In
Participants receive 1 infusion of CARv3-TEAM-E, with staggered enrollment and evaluation for dose-limiting toxicities
Treatment
Participants receive CARv3-TEAM-E T Cells weekly for 6 doses
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Participants are monitored for long-term safety and survival outcomes
Treatment Details
Interventions
- CARv3-TEAM-E T Cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
Marcela V. Maus, M.D.,Ph.D.
Lead Sponsor